CP 544326: structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 18376177 |
| CHEMBL ID | 2107783 |
| SCHEMBL ID | 3318549 |
| MeSH ID | M0569393 |
| Synonym |
|---|
| bdbm50016953 |
| taprenepag |
| 752187-80-7 |
| taprenepag (usan/inn) |
| D09968 |
| 2-(3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino) methyl)phenoxy)acetic acid |
| cp 544326 |
| acetic acid, 2-(3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino) methyl)phenoxy)- |
| 9cd894kumj , |
| cp-544326 |
| unii-9cd894kumj |
| pf 04217329 |
| taprenepag [usan:inn] |
| CHEMBL2107783 |
| gtpl5816 |
| 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid |
| SCHEMBL3318549 |
| pf04217329 |
| taprenepag [usan] |
| taprenepag [who-dd] |
| 2-(3-((n-((4-(1h-pyrazol-1-yl)phenyl)methyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid |
| taprenepag [inn] |
| cp544326 |
| acetic acid, (3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)phenoxy)- |
| acetic acid, 2-(3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)phenoxy)- |
| 2-(3-{[{[4-(1h-pyrazol-1-yl)phenyl]methyl}(pyridin-3-ylsulfonyl)amino]methyl}phenoxy)acetic acid |
| DTXSID00226187 |
| CS-5590 |
| HY-14899 |
| J-690347 |
| EX-A941 |
| acetic acid, [3-[[[[4-(1h-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]- |
| mfcd18633300 |
| AKOS030632799 |
| taprenepag(cp-544326) |
| DB12623 |
| A858259 |
| BCP17228 |
| BCP24232 |
| Q27088938 |
| 2-(3-((n-(4-(1h-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid |
| 2-[3-[[[[4-(1h-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]acetic acid; cp 544326 |
| AS-76944 |
| 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonyl-amino]methyl]phenoxy]ethanoic acid |
| GNO , |
| CFB18780 |
| 2-(3-((n-(4-(1h-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)aceticacid |
| AC-36845 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | Ki | 3.2000 | AID1151360 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | Ki | 3.2000 | AID1151362 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | Ki | 3.2000 | AID1151361 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | Ki | 0.0100 | AID1151359 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | EC50 | 0.0028 | AID1151368 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1151362 | Binding affinity to EP4 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151373 | Selectivity ratio of Ki for EP4 receptor (unknown origin) to Ki for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151369 | Agonist activity at prostanoid IP receptor (unknown origin) by functional assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151372 | Selectivity ratio of Ki for EP3 receptor (unknown origin) to Ki for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151359 | Binding affinity to EP2 receptor (unknown origin) by competitive binding assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151361 | Binding affinity to EP3 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151368 | Agonist activity at EP2 receptor (unknown origin) by functional assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151363 | Binding affinity to prostanoid IP receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151371 | Selectivity ratio of Ki for EP1 receptor (unknown origin) to Ki for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151360 | Binding affinity to EP1 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 ISSN: 1520-4804 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1346318 | Rat EP2 receptor (Prostanoid receptors) | 2011 | Experimental eye research, Sep, Volume: 93, Issue:3 ISSN: 1096-0007 | Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. |
| AID1346308 | Human EP2 receptor (Prostanoid receptors) | 2011 | Experimental eye research, Sep, Volume: 93, Issue:3 ISSN: 1096-0007 | Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (50.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ah 6809 | xanthones | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| 2-[[2-furanyl(oxo)methyl]amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid ethyl ester | organosulfur heterocyclic compound | 2014 | 2014 | 10.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | ||
| dinoprostone | prostaglandins E | human metabolite; mouse metabolite; oxytocic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| butaprost | 2014 | 2014 | 10.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |||
| tg4-155 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| cp533536 | monocarboxylic acid | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| pf-04418948 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| tg6-10-1 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| phenyl acetate | benzenes; phenyl acetates | 2011 | 2019 | 10.4 | high | 2 | 0 | 0 | 0 | 5 | 0 | ||
| dinoprostone | prostaglandins E | human metabolite; mouse metabolite; oxytocic | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| latanoprost | isopropyl ester; prostaglandins Falpha; triol | antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug | 2011 | 2013 | 12.0 | medium | 2 | 0 | 0 | 0 | 2 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apoplexy | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Chronic Primary Open Angle Glaucoma | 0 | 2011 | 2013 | 12.3 | medium | 2 | 0 | 0 | 0 | 3 | 0 | |
| Corneal Diseases | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Degenerative Diseases, Central Nervous System | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Eye Diseases | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Eye Disorders | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Glaucoma | 0 | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 | |
| Glaucoma, Open-Angle | 0 | 2011 | 2013 | 12.3 | medium | 2 | 0 | 0 | 0 | 3 | 0 | |
| Glaucoma, Suspect | 0 | 2011 | 2013 | 12.0 | low | 2 | 0 | 0 | 0 | 2 | 0 | |
| Intraocular Pressure | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Neurodegenerative Diseases | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Ocular Hypertension | 0 | 2011 | 2013 | 12.0 | low | 2 | 0 | 0 | 0 | 2 | 0 | |
| Stroke | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Experimental eye research, , Volume: 93, Issue:3 | 2011 |
| Article | Year |
|---|---|
| Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, , Volume: 30, Issue:5 | 2014 |
| A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Current eye research, , Volume: 36, Issue:9 | 2011 |
| Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Experimental eye research, , Volume: 93, Issue:3 | 2011 |